SCHEMBL177637

SCHEMBL177637

Cc1ccc(OBOc2ccc(C)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 5/20 0.52
TDP1 Q9NUW8 2/20 0.47
TSHR P16473 2/20 0.44
CYP3A4 P08684 1/20 0.44
TEAD4 Q15561 1/20 0.44
ALDH1A1 P00352 2/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
LMNA P02545 1/20 0.42
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
RELA Q04206 1/20 0.41
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
DRD3 P35462 1/20 0.37
WDR5 P61964 1/20 0.37
CA7 P43166 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2309012 0.86 TSHR (0.41) ACHETDP1TSHRCYP3A4TEAD4
SCHEMBL363120 0.82 ACHE (0.52) ACHETDP1ALDH1A1POLBMEN1
SCHEMBL20557364 0.81 ACHE (0.41) ACHETDP1TSHRCYP3A4TEAD4
SCHEMBL342740 0.81 DRD2 (0.44) ACHETDP1TSHRALDH1A1MAPT
SCHEMBL28956767 0.79 ACHE (0.39) ACHETDP1TSHRCYP3A4TEAD4
SCHEMBL2602434 0.78 ACHE (0.48) ACHETDP1TSHRCYP3A4TEAD4
SCHEMBL21889 0.77 CA1 (0.65) ACHETDP1CYP3A4ALDH1A1MAPT
SCHEMBL15744763 0.72 ACHE (0.42) ACHETDP1TSHRCYP3A4TEAD4
SCHEMBL452367 0.72 MAPT (0.52) TDP1TSHRALDH1A1POLBMAPT
SCHEMBL83863 0.71 TEAD4 (0.74) ACHETDP1TSHRCYP3A4TEAD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 926 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12478615-B2 Prolyl hydroxylase inhibitors and methods of use AKEBIA THERAPEUTICS, INC. (US) 2025-11-25 US claimed
CN-118922186-A Novel compound and composition for preventing, alleviating or treating bacterial inflammation and inflammation-related disorder containing the same as active ingredient 客融生物有限公司 2024-11-08 CN claimed
US-20240358691-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE WARNER CHILCOTT COMPANY, LLC (PR) 2024-10-31 US claimed
EP-3478792-B1 CHEMILUMINESCENT SUBSTRATES BECKMAN COULTER INC (US) 2023-12-13 EP claimed
US-11495769-B2 Inorganic light emitting diode and inorganic light emitting device including the same LG DISPLAY CO., LTD. (KR) 2022-11-08 US claimed
US-20210167321-A1 INORGANIC LIGHT EMITTING DIODE AND INORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME LG DISPLAY CO., LTD. (KR) 2021-06-03 US claimed
US-10703971-B2 Chemiluminescent substrates BECKMAN COULTER, INC. (US) 2020-07-07 US claimed
US-20190161675-A1 CHEMILUMINESCENT SUBSTRATES BECKMAN COULTER, INC. (US) 2019-05-30 US claimed
EP-3478792-A1 CHEMILUMINESCENT SUBSTRATES Beckman Coulter Inc. (US) 2019-05-08 EP claimed
EP-3122707-B1 METHOD FOR COUPLING A FIRST AROMATIC COMPOUND TO A SECOND AROMATIC COMPOUND DOW GLOBAL TECHNOLOGIES LLC (US) 2018-04-25 EP claimed
EP-3149138-A1 WATER CLUSTER-DOMINANT BORONIC ACID ALKALI SURFACTANT COMPOSITIONS AND THEIR USE The Procter & Gamble Company (US) 2017-04-05 EP claimed
WO-2015184209-A1 WATER CLUSTER-DOMINANT BORONIC ACID ALKALI SURFACTANT COMPOSITIONS AND THEIR USE THE PROCTER & GAMBLE COMPANY (US) 2015-12-03 WO claimed
US-20150344817-A1 WATER CLUSTER-DOMINANT BORONIC ACID ALKALI SURFACTANT COMPOSITIONS AND THEIR USE THE PROCTER & GAMBLE COMPANY 2015-12-03 US claimed
US-8921299-B2 Detergents having acceptable color THE PROCTER & GAMBLE COMPANY (US) 2014-12-30 US claimed
EP-1351963-B1 A PROCESS FOR THE SYNTHESIS OF ATORVASTATIN FORM V AND PHENYLBORONATES AS INTERMEDIATE COMPOUNDS BIOCON LTD (IN) 2010-08-18 EP claimed
US-6867306-B2 Process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds BIOCON LIMITED (IN) 2005-03-15 US claimed
US-20040072893-A1 Process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds BIOCON INDIA LIMITED (IN) 2004-04-15 US claimed
EP-1351963-A1 A PROCESS FOR THE SYNTHESIS OF ATORVASTATIN FORM V AND PHENYLBORONATES AS INTERMEDIATE COMPOUNDS Biocon India Limited (IN) 2003-10-15 EP claimed
WO-2002057274-A1 A PROCESS FOR THE SYNTHESIS OF ATORVASTATIN FORM V AND PHENYLBORONATES AS INTERMEDIATE COMPOUNDS BIOCON INDIA LIMITED (IN) 2002-07-25 WO claimed
WO-1995005081-A1 BIOCIDAL COMPOSITIONS CONTAINING ORGANOBORON COMPOUNDS U.S. BORAX INC. (US) 1995-02-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240358691-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE HIF1AN, EGLN3, EGLN2 ACHE 4874/4885TDP1 2317/4885TSHR 2646/4885
US-12478615-B2 Prolyl hydroxylase inhibitors and methods of use HIF1AN, EGLN3, HIF1A ACHE 4874/4885TDP1 1974/4885TSHR 2703/4885
US-20040072893-A1 Process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds HMGCR, DHCR7, GRHPR ACHE 2113/4885TDP1 3752/4885TSHR 3101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.